Logo image of ALGS

ALIGOS THERAPEUTICS INC (ALGS) Stock Fundamental Analysis

NASDAQ:ALGS - Nasdaq - US01626L2043 - Common Stock - Currency: USD

9.13  +0.22 (+2.47%)

Premarket: 8.46 -0.67 (-7.34%)

Fundamental Rating

2

Overall ALGS gets a fundamental rating of 2 out of 10. We evaluated ALGS against 553 industry peers in the Biotechnology industry. While ALGS seems to be doing ok healthwise, there are quite some concerns on its profitability. ALGS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALGS has reported negative net income.
ALGS had a negative operating cash flow in the past year.
In the past 5 years ALGS always reported negative net income.
In the past 5 years ALGS always reported negative operating cash flow.
ALGS Yearly Net Income VS EBIT VS OCF VS FCFALGS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ALGS's Return On Assets of -35.34% is fine compared to the rest of the industry. ALGS outperforms 60.76% of its industry peers.
With a decent Return On Equity value of -45.74%, ALGS is doing good in the industry, outperforming 67.45% of the companies in the same industry.
Industry RankSector Rank
ROA -35.34%
ROE -45.74%
ROIC N/A
ROA(3y)-103.51%
ROA(5y)-81.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALGS Yearly ROA, ROE, ROICALGS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALGS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALGS Yearly Profit, Operating, Gross MarginsALGS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

4

2. Health

2.1 Basic Checks

ALGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALGS has less shares outstanding
The number of shares outstanding for ALGS has been reduced compared to 5 years ago.
Compared to 1 year ago, ALGS has a worse debt to assets ratio.
ALGS Yearly Shares OutstandingALGS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ALGS Yearly Total Debt VS Total AssetsALGS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

ALGS has an Altman-Z score of -5.15. This is a bad value and indicates that ALGS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -5.15, ALGS is not doing good in the industry: 60.58% of the companies in the same industry are doing better.
ALGS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ALGS has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.15
ROIC/WACCN/A
WACC9.82%
ALGS Yearly LT Debt VS Equity VS FCFALGS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

ALGS has a Current Ratio of 7.56. This indicates that ALGS is financially healthy and has no problem in meeting its short term obligations.
ALGS's Current ratio of 7.56 is fine compared to the rest of the industry. ALGS outperforms 68.72% of its industry peers.
A Quick Ratio of 7.56 indicates that ALGS has no problem at all paying its short term obligations.
ALGS has a Quick ratio of 7.56. This is in the better half of the industry: ALGS outperforms 69.08% of its industry peers.
Industry RankSector Rank
Current Ratio 7.56
Quick Ratio 7.56
ALGS Yearly Current Assets VS Current LiabilitesALGS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

ALGS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.69%, which is quite impressive.
ALGS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -76.30%.
The Revenue has been decreasing by -3.28% on average over the past years.
EPS 1Y (TTM)75.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.64%
Revenue 1Y (TTM)-76.3%
Revenue growth 3Y-3.28%
Revenue growth 5YN/A
Sales Q2Q%-68.46%

3.2 Future

ALGS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.64% yearly.
Based on estimates for the next years, ALGS will show a very strong growth in Revenue. The Revenue will grow by 137.71% on average per year.
EPS Next Y11.45%
EPS Next 2Y8.99%
EPS Next 3Y5.52%
EPS Next 5Y27.64%
Revenue Next Year-50.08%
Revenue Next 2Y-13.02%
Revenue Next 3Y-13.19%
Revenue Next 5Y137.71%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALGS Yearly Revenue VS EstimatesALGS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
ALGS Yearly EPS VS EstimatesALGS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALGS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALGS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALGS Price Earnings VS Forward Price EarningsALGS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALGS Per share dataALGS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.99%
EPS Next 3Y5.52%

More info and screens

0

5. Dividend

5.1 Amount

ALGS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALIGOS THERAPEUTICS INC

NASDAQ:ALGS (7/25/2025, 8:00:00 PM)

Premarket: 8.46 -0.67 (-7.34%)

9.13

+0.22 (+2.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-04 2025-08-04/amc
Inst Owners62.1%
Inst Owner Change0%
Ins Owners2.14%
Ins Owner Change0%
Market Cap55.78M
Analysts84
Price Target86.96 (852.46%)
Short Float %11.2%
Short Ratio3.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.74%
Min EPS beat(2)-33.51%
Max EPS beat(2)26.03%
EPS beat(4)2
Avg EPS beat(4)18.14%
Min EPS beat(4)-39.56%
Max EPS beat(4)119.61%
EPS beat(8)5
Avg EPS beat(8)13.67%
EPS beat(12)7
Avg EPS beat(12)12.74%
EPS beat(16)9
Avg EPS beat(16)9.02%
Revenue beat(2)1
Avg Revenue beat(2)16.89%
Min Revenue beat(2)-8.53%
Max Revenue beat(2)42.31%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.75%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.97%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)30%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-92.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.06
P/FCF N/A
P/OCF N/A
P/B 0.48
P/tB 0.48
EV/EBITDA N/A
EPS(TTM)-7.78
EYN/A
EPS(NY)-9.07
Fwd EYN/A
FCF(TTM)-12.93
FCFYN/A
OCF(TTM)-12.91
OCFYN/A
SpS0.54
BVpS19.06
TBVpS19.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.34%
ROE -45.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.51%
ROA(5y)-81.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.08%
Cap/Sales 3.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.56
Quick Ratio 7.56
Altman-Z -5.15
F-Score3
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)18.19%
Cap/Depr(5y)31.84%
Cap/Sales(3y)3.39%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.64%
EPS Next Y11.45%
EPS Next 2Y8.99%
EPS Next 3Y5.52%
EPS Next 5Y27.64%
Revenue 1Y (TTM)-76.3%
Revenue growth 3Y-3.28%
Revenue growth 5YN/A
Sales Q2Q%-68.46%
Revenue Next Year-50.08%
Revenue Next 2Y-13.02%
Revenue Next 3Y-13.19%
Revenue Next 5Y137.71%
EBIT growth 1Y1.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y3.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3%
OCF growth 3YN/A
OCF growth 5YN/A